Back

One Day Hospital Initiation of Oral Sotalol The Cmax ss Test Strategy

Molnar, J.; Somberg, J.

2026-03-14 cardiovascular medicine
10.64898/2026.03.12.26348293 medRxiv
Show abstract

BACKGROUNDSotalol loading intravenously enables achieving blood levels of sotalol that are observed at maximal steady-state concentration (Cmax ss) in one-day permitting the measurement of maximum QTc effects. Rapid evaluation of the QTc effects permits determination of arrhythmic risk and thus permits discharge in 24-hours instead of the usual three-day oral load hospitalization. Given the expense of IV Sotalol an oral loading test strategy is presented that also achieves Cmax ss blood levels rapidly, permitting a one-day hospitalization for QTc evaluation. METHODPharmacokinetic parameters referred to in the literature derived from normals as well as patients was utilized for population pharmacokinetic modeling and simulation.to obtain the Cmax ss concentrations for patients with normal renal function, creatinine clearance (CrCl) > 90 ml/min), as well as for patients with a CrCl of 60-89, 30-59, and 10-29 ml/min). Using pharmacokinetic simulations, an oral loading dose, as well as a second oral dose were determined that would reach the estimated Cmax ss in each of the groups based on renal function. RESULTSFor target dosing of 120 mg oral sotalol BID in patients with a CrCl >90 ml/min an oral loading dose of 200 mg provides a peak sotalol level of 1,420 ng/ml in 3-4 hours post dosing. The Cmax ss target is 1,299 ng/ml resulting in a 9% overshoot. The Cmax ss concentration provides a means of evaluating QTc effects within 24-hours. Oral loading regimens are described for varying additional renal function levels (CrCl 60-90, 30-59 and 10-29 ml/min) along with the time to first oral dose and follow-up dosing. The initial test dose can be based on an 80 or 120 mg oral sotalol maintenance dosing strategy. CONCLUSIONSEmploying an oral loading strategy may permit QTc evaluation and one-day discharge, preserving the pharmacoeconomic advantage of a Cmax ss test strategy. Clinical PerspectiveO_ST_ABSWhat is Known?C_ST_ABSO_LIIntravenously loading of sotalol enables achieving blood levels that are observed at maximal steady-state concentration (Cmax ss) in one-day permitting the measurement of maximum QTc effects. C_LIO_LIRapid evaluation of the QTc effects permits determination of arrhythmic risk and thus permits discharge in 24-hours instead of the usual three-day oral load hospitalization C_LI What the Study AddsO_LIWith oral sotalol loading, the Cmax ss can also be achieved in one-day permitting the measurement of maximum QTc effects and discharge from the hospital in 24-hours instead of the usual three-day inpatient initiation of oral sotalol. C_LI

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
British Journal of Clinical Pharmacology
21 papers in training set
Top 0.1%
18.1%
2
Clinical Pharmacology & Therapeutics
25 papers in training set
Top 0.1%
12.0%
3
Heart Rhythm
22 papers in training set
Top 0.1%
12.0%
4
Cureus
67 papers in training set
Top 0.3%
8.2%
50% of probability mass above
5
Frontiers in Pharmacology
100 papers in training set
Top 0.4%
6.2%
6
PLOS ONE
4510 papers in training set
Top 29%
6.1%
7
Open Heart
19 papers in training set
Top 0.3%
3.9%
8
BMJ Open
554 papers in training set
Top 8%
2.0%
9
Pilot and Feasibility Studies
12 papers in training set
Top 0.2%
2.0%
10
Journal of the American Heart Association
119 papers in training set
Top 3%
2.0%
11
Scientific Reports
3102 papers in training set
Top 54%
1.8%
12
Heart
10 papers in training set
Top 0.5%
1.7%
13
The American Journal of Cardiology
15 papers in training set
Top 0.9%
1.7%
14
BMC Cardiovascular Disorders
14 papers in training set
Top 1%
1.6%
15
Journal of Family Medicine and Primary Care
10 papers in training set
Top 0.3%
1.3%
16
Clinical and Translational Science
21 papers in training set
Top 0.6%
1.2%
17
Trials
25 papers in training set
Top 1%
0.9%
18
BMC Infectious Diseases
118 papers in training set
Top 5%
0.9%
19
Contemporary Clinical Trials Communications
11 papers in training set
Top 0.5%
0.9%
20
Open Forum Infectious Diseases
134 papers in training set
Top 2%
0.9%
21
Neurocritical Care
11 papers in training set
Top 0.3%
0.9%
22
Frontiers in Physiology
93 papers in training set
Top 6%
0.8%